The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.
The firm's diagnostics revenues also grew 6 percent year over year with molecular diagnostics revenues up 9 percent.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.
The firm is looking to expand its sales internationally, as well as in the consumer-initiated market, but is being conservative with revenue growth estimates.
The firm said that total revenue was lower than expected due to the timing of orders in its flow cytometry operations in the third quarter.
The Temple City, California-based NGS genetic testing firm more than doubled its number of billable tests compared to the prior-year period.
The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.
The New York Times reports on how environmental DNA sampling could monitor endangered species.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.